A phase <scp>II</scp> trial of regorafenib in patients with advanced Ewing sarcoma and related tumors of soft tissue and bone: <scp>SARC024</scp> trial results

202253 citationsJournal Articlegold Open Access

Authors

Regorafenib has modest activity in the Ewing family sarcomas. Toxicity was similar to that seen in approval studies.

Good health and well-being

Published in: Cancer Medicine

Volume 12, Issue 2, pp. 1532-1539

Field-Weighted Citation Impact: 5.78